欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2009, Vol. 14 ›› Issue (8): 915-923.

• 定量药理学 • 上一篇    下一篇

参松养心胶囊治疗室性早搏随机对照试验的系统评价

李延鸿1, 朱怀军2   

  1. 1广州市第十二人民医院药剂科, 广州 510620, 广东;
    2南京大学医学院附属鼓楼医院药剂科, 南京 210008, 江苏
  • 收稿日期:2009-06-30 修回日期:2009-07-08 出版日期:2009-08-26 发布日期:2020-10-30
  • 作者简介:李延鸿, 男, 本科, 临床药师, 研究方向:临床药学。Tel:13078848018 E-mail:liyanhong12@126.com

Systematic review on randomized controlled trials for treatment of ventricular premature beat(VPB) by ShensongYangxin capsule

LI Yan-hong1, ZHU Huai-jun2   

  1. 1Guangzhou12thHospital, Guangzhou 510620, Guangdong, China;
    2Affliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, Jiangsu, China
  • Received:2009-06-30 Revised:2009-07-08 Online:2009-08-26 Published:2020-10-30

摘要: 目的: 探讨参松养心胶囊与对照药物治疗室性早搏的有效性及安全性的差异。方法: 应用Meta 分析 21 篇关于参松养心胶囊与其它常用治疗室性早搏药治疗室性早搏的研究文献, 对其有效性及安全性进行同质性检验及合并效应量的估计。结果: 同质性检验:心电图疗效有效性:χ2=25.20, df=17, P=0.090;临床疗效有效性 :χ2=26.10, df=11, P=0.006;室性早搏疗效有效性:χ2=7.13, df=5, P=0.211;安全性 1 χ2=31.14,df=20, P=0.053, 安全性 2χ2=30.37, df=20, P=0.064。合并效应量的估计, 有效性:心电图疗效OR合并=1.04, OR合并 95%可信区间为[1.00,1.09]。临床疗效 OR合并=1.33, OR合并 95%可信区间为[1.19, 1.48]。室性早搏疗效 OR合并=1.25, OR合并 95%可信区间为[1.13, 1.39]。 安全性 1OR合并=0.38, OR合并 95%可 信 区 间 为 [0.28,0.52];安全性 2 OR合并=0.39, OR合并 95%可信区间为[0.29, 0.52]。结论: 参松养心胶囊治疗室性早搏有优于对照组的趋势, 安全性比较优于对照组且有统计学差异。

关键词: 参松养心胶囊, 室性早搏, Meta 分析, 随机对照试验, 系统评价

Abstract: AIM: To evaluate the curative effect difference between ShensongYangxincapsule and Con-trol Group and the safety of them on ventricular prema-ture beat (VPB) .METHODS: Meta-analysis of 21-ShensongYangxin Capsule on the parameters commonly used treatment of VPB and other research literature on drug treatment of VPB, its effectiveness and safety for homogeneity test and the combined effect size estimate. RESULTS: Homogeneity test :Clinical effectiveness of the ECG :χ2=25.20, df=17, P=0 .090;Clinical ef-fectiveness:χ2=26.10, df=11, P=0.006;Clinical effectiveness of ventricular premature beats:χ2=7.13, df=5, P=0.211;Security 1 χ2=31.14, df=20, P=0.053, Security 2χ2=30.37, df=20, P=0.064.Combined effect size estimates: Effectiveness: Clinical effectiveness of the ECG:OR affiliate=1.04, 95%confidence interval of OR was [1.00, 1.09], Clinical effectiveness: OR affiliate=1.33, 95% confi-dence interval of OR was [1.19, 1.48] , Clinical ef-fectiveness of ventricular premature beats:OR affiliate=1.25, 95 % confidence interval of OR was [1 .13, 1.39] , Security 1 :OR affiliate=0.38, 95% confi-dence interval of OR was [0.28, 0.52] , Security 2: OR affiliate=0.39, 95% confidence interval of OR was [0.29, 0.52].CONCLUSION: The treatment of VPB ShensongYangxin capsule is better than the control group, Comparison of safety is also better control group and there is a significant difference .

Key words: ShensongYangxin capsule, ventricular premature beat, Meta analysis, randomized controlled trial, systematic review

中图分类号: